Cancer Communications | |
Targeted therapy: resistance and re-sensitization | |
Dao-Hong Chen3  Xiao-Shi Zhang4  | |
[1] Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China;State Key Laboratory of Oncology in South China;Biomedical Research Institute, Yiling Pharmaceutical Company, Beijing, P. R. China;Biotherapy Center, Sun Yat-sen University Cancer Center | |
关键词: Targeted therapy; Drug resistance; Re-sensitization; | |
DOI : 10.1186/s40880-015-0047-1 | |
学科分类:肿瘤学 | |
来源: Springer | |
【 摘 要 】
The last two decades have witnessed a paradigm shift from cytotoxic drugs to targeted therapy in medical oncology and pharmaceutical innovation. Inspired by breakthroughs in molecular and cellular biology, a number of novel synthesized chemical compounds and recombinant antibodies have been developed to selectively target oncogenic signaling pathways in a broad array of tumor types. Although targeted therapeutic agents show impressive clinical efficacy and minimized adverse effects compared with traditional treatments, the challenging drug-resistant issue has also emerged to limit their benefits to cancer patients. In this regard, we aim to improve targeted therapy by presenting a systematic framework regarding the drug resistance mechanisms and alternative approaches to re-sensitize cancer cells/tissues therapeutically.
【 授权许可】
CC BY
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201904021800001ZK.pdf | 786KB | download |